COMMUNIQUÉS West-GlobeNewswire

Appointment of Dr. Kalpesh Barot, MD Completes Phase One of ADIA Nutrition’s Medical Division
24/09/2024
WINTER PARK, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition (OTC Pink: ADIA) is excited to announce the completion of its Board of Medical Directors with the appointment of Dr. Kalpesh Barot, MD, a [...]
NeuroOne® Spinal Cord Stimulation Electrode Technology to be Featured at The Business of Pain Conference
24/09/2024
Minimally invasive technology would allow for percutaneous placement of a paddle electrode Renowned pain specialist Dr. Sean Li to present on this innovative tool for lower back pain EDEN PRAIRIE, Minn., Sept. 24, 2024 [...]
AAMI, CTA to Collaborate on AI Standards
24/09/2024
Arlington, Virginia, Sept. 24, 2024 (GLOBE NEWSWIRE) -- As artificial intelligence (AI) becomes more integrated into the healthcare sector, there is a pressing need for industry standards that will protect patients and [...]
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
24/09/2024
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the [...]
Lighthouse Autism Center Announces Expansion of ABA Services in Iowa
24/09/2024
Leading ABA Provider Set to Open Newest Location in Cedar Rapids, IA. CEDAR RAPIDS, Iowa, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lighthouse Autism Center, a premier provider of center-based Applied Behavior Analysis (ABA) [...]
Georgiamune Announces First Participant Dosed in First-In-Class Phase 1 Healthy Volunteers Trial of GIM-407
24/09/2024
Georgiamune continues biotech innovation streak with first autoimmune disease-focused program based on novel biology GAITHERSBURG, Md., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Today, Georgiamune Inc . , a privately held, [...]
Conception Nurseries Launches TrueClones™ X
24/09/2024
The Industry’s First Generation Zero Hardened Tissue-Cultured Clones Provides Cannabis Cultivators With a Faster Path to Profit SACRAMENTO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Conception Nurseries , the world’s [...]
Tersa Earth and Silica-X Sign MoU to Revolutionize Mining and Waste Management with AI-Powered Biotech and Zero-Waste Solutions
24/09/2024
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fresh off its recognition as a Top Innovator in the World Economic Forum’s (WEF) Sustainable Mining Challenge, Tersa Earth Innovations Inc. announces signing a Memorandum of [...]
Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide
24/09/2024
The new Lu-177 production facility further solidifies Curium’s position as a global leader in nuclear medicine Curium will ensure a continuous supply of Lu-177 to benefit more than 100,000 cancer patients worldwide over [...]
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology – Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference
24/09/2024
VANCOUVER, British Columbia, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) reports that it will be presenting the Company’s [...]
Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration
24/09/2024
Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wingless/Integrated (Wnt) [...]
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
24/09/2024
VANCOUVER, Washington, Sept. 24, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple [...]
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
24/09/2024
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, [...]
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
24/09/2024
Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the independent Data [...]
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
24/09/2024
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ET Continued progress within core activities in RNA delivery, supported by move into new R&D facilities [...]
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”
24/09/2024
TRxADE Health, Inc. today announced that it changed its name and ticker symbol to “Scienture Holdings, Inc.” and “SCNX”, respectively, and that the business will continue as a Nasdaq-listed company. TAMPA, FL, Sept. 24 [...]
Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner
24/09/2024
TEMPE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, announced today that it received a 2024 AZBio™ Fast Lane [...]
Spectral AI Achieves 25% Patient Enrollment at Emergency Departments for U.S. Burn Pivotal Study and Adds Two New Clinical Trial Sites
24/09/2024
DALLAS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
24/09/2024
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025 Almost half of the 9 million individuals in the United States with plaque psoriasis experience [...]

Pages